ATE239484T1 - Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen - Google Patents

Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen

Info

Publication number
ATE239484T1
ATE239484T1 AT92923139T AT92923139T ATE239484T1 AT E239484 T1 ATE239484 T1 AT E239484T1 AT 92923139 T AT92923139 T AT 92923139T AT 92923139 T AT92923139 T AT 92923139T AT E239484 T1 ATE239484 T1 AT E239484T1
Authority
AT
Austria
Prior art keywords
nucleoside
substituent
molecule
linking group
soluble vitamin
Prior art date
Application number
AT92923139T
Other languages
English (en)
Inventor
Muthiah Manoharan
Philip Dan Cook
Clarence Frank Bennett
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE239484T1 publication Critical patent/ATE239484T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92923139T 1991-10-24 1992-10-23 Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen ATE239484T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78237491A 1991-10-24 1991-10-24
PCT/US1992/009196 WO1993007883A1 (en) 1991-10-24 1992-10-23 Derivatized oligonucleotides having improved uptake and other properties

Publications (1)

Publication Number Publication Date
ATE239484T1 true ATE239484T1 (de) 2003-05-15

Family

ID=25125854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92923139T ATE239484T1 (de) 1991-10-24 1992-10-23 Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen

Country Status (7)

Country Link
EP (2) EP1331011A3 (de)
JP (1) JP2823959B2 (de)
AT (1) ATE239484T1 (de)
AU (1) AU2916292A (de)
CA (1) CA2122030C (de)
DE (1) DE69233046T2 (de)
WO (1) WO1993007883A1 (de)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5578718A (en) * 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5998603A (en) * 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
US5688941A (en) * 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US6713602B1 (en) 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US6071699A (en) 1996-06-07 2000-06-06 California Institute Of Technology Nucleic acid mediated electron transfer
US5886177A (en) * 1994-01-11 1999-03-23 Isis Pharmaceuticals, Inc. Phosphate linked oligomers
US6448373B1 (en) 1994-01-11 2002-09-10 Isis Pharmaceuticals, Inc. Phosphate linked oligomers formed of monomeric diols and processes for preparing same
US6184389B1 (en) 1994-01-11 2001-02-06 Isis Pharmaceuticals, Inc. Combinatorial libraries having aminodiol monomer subunits
US6828427B1 (en) 1994-01-11 2004-12-07 Isis Pharmaceuticals, Inc. Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5646269A (en) * 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
FR2727970A1 (fr) * 1994-12-12 1996-06-14 Inst Nat Sante Rech Med Conjugues fullerene-oligonucleotide, ou fullerene-nucleotide leurs complexes avec des nanoparticules et leurs utilisations therapeutiques
EP0813539B1 (de) * 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
EP0877751B1 (de) * 1995-12-22 2003-10-15 University Technologies International Inc. Kupplungsarm für festträger oligonukleotid-synthese und verfahren zur herstellung davon
US5834198A (en) * 1996-03-21 1998-11-10 Boehringer Mamnnheim Gmbh Selective photoinducted flavin-dependent cleavage of RNA at G-U base pairs and kits therefor
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
ATE251638T1 (de) 1996-06-06 2003-10-15 Novartis Pharma Gmbh 2-substituierte nukleosid- und oligonukleotid- derivate
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0856579A1 (de) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
AU750451B2 (en) * 1997-02-13 2002-07-18 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6127533A (en) * 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
AU9377498A (en) 1997-09-05 1999-03-22 Isis Pharmaceuticals, Inc. Substituted cyclic compounds and mixtures comprising same
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
AU4328399A (en) * 1998-06-15 2000-01-05 Alza Corporation Nucleic acid-cobalamin complexes and their use in gene therapy
WO2000001711A1 (en) * 1998-07-02 2000-01-13 University Technologies International Inc. Reusable solid support for oligonucleotide synthesis
CA2336384A1 (en) * 1998-07-02 2000-01-13 The Trustees Of Columbia University In The City Of New York Oligonucleotide inhibitors of bcl-xl
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
SE9803099D0 (sv) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
US6403779B1 (en) 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6277982B1 (en) 1999-08-20 2001-08-21 Isis Pharmaceuticals, Inc. Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
IL153378A0 (en) 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US6809195B1 (en) 2000-08-16 2004-10-26 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotides
DE10048091A1 (de) * 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
WO2002045707A2 (en) * 2000-12-06 2002-06-13 Lyles Mark B Polynucleotide intercalator interceptors and inhibitors
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
ES2424269T3 (es) * 2002-11-01 2013-09-30 Iris International, Inc. Inmuno-PCR sándwich por desplazamiento
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1560840B1 (de) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Zusammensetzungen, die alternierende 2'-modifizierte nucleoside enthalten, zur verwendung in der genmodulation
US6913890B2 (en) 2002-12-18 2005-07-05 Palo Alto Research Center Incorporated Process for preparing albumin protein conjugated oligonucleotide probes
EP2336317B1 (de) 2003-06-13 2019-09-11 Alnylam Europe AG Doppelsträngige Ribonukleinsäure mit gesteigerter Wirksamkeit in einem Organismus
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
JP4584987B2 (ja) * 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
WO2006112872A2 (en) * 2004-08-04 2006-10-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
PT1815028E (pt) 2004-11-03 2012-01-24 Iris Molecular Diagnostics Inc Microbolhas para separação por afinidade
JP5188808B2 (ja) 2004-11-03 2013-04-24 アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド 同種の分析物検出
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US7320965B2 (en) 2005-10-28 2008-01-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Huntingtin gene
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
AU2006311730B2 (en) 2005-11-09 2010-12-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
EP2388327A1 (de) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
SG171676A1 (en) 2006-05-11 2011-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
CA2663581C (en) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
KR101488800B1 (ko) 2007-02-09 2015-02-04 노오쓰웨스턴 유니버시티 세포내 타겟 검출용 입자
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
CA3055145A1 (en) 2007-05-30 2008-12-11 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2009004085A2 (en) 2007-07-05 2009-01-08 Novartis Ag Dsrna for treating viral infection
JP5710977B2 (ja) * 2007-11-05 2015-04-30 バルティック テクノロジー デヴェロプメント，リミテッド 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用
FR2931152B1 (fr) * 2008-05-16 2010-07-30 Centre Nat Rech Scient Nouveau systeme de transfert d'acide nucleique
CN106955360A (zh) 2008-11-24 2017-07-18 西北大学 多价rna纳米颗粒组合物
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
SG173182A1 (en) 2009-02-03 2011-09-29 Hoffmann La Roche Compositions and methods for inhibiting expression of ptp1b genes
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
EP3252068B1 (de) 2009-10-12 2025-07-02 Larry J. Smith Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
US20110112176A1 (en) 2009-11-09 2011-05-12 John Frederick Boylan Compositions and methods for inhibiting expression of kif10 genes
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
US20110196016A1 (en) 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
ES2743600T3 (es) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Métodos de tratamiento de los trastornos inflamatorios vasculares
NZ603339A (en) 2010-04-29 2015-01-30 Isis Pharmaceuticals Inc Modulation of transthyretin expression
EP2630240A1 (de) 2010-10-18 2013-08-28 Arrowhead Research Corporation Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
CN106434665B (zh) 2011-06-30 2021-06-08 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
EP2755692B1 (de) 2011-09-14 2020-11-25 Northwestern University Nanokonjugate zur durchquerung der blut-hirn-schranke
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
SG11201503821YA (en) 2012-11-15 2015-06-29 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
RU2649367C2 (ru) 2013-01-30 2018-04-02 Ф. Хоффманн-Ля Рош Аг Конъюгаты углевода и lna-олигонуклеотида
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
EP3047023B1 (de) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zusammensetzungen und methoden zur inhibierung des jc virus (jcv)
EP3052107B1 (de) 2013-10-04 2018-05-02 Novartis AG Organische verbindungen zur behandlung von hepatitis-b-infektionen
CN105683163B (zh) 2013-10-04 2018-11-09 诺华股份有限公司 RNA干扰中使用的RNAi剂的3’端帽
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3256487A4 (de) 2015-02-09 2018-07-18 Duke University Zusammensetzungen und verfahren zur epigenombearbeitung
US10961532B2 (en) 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
EP4089175A1 (de) 2015-10-13 2022-11-16 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
CA2999649A1 (en) 2015-11-06 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1a
UA125963C2 (uk) 2015-11-12 2022-07-20 Ф. Хоффманн-Ля Рош Аг Олігонуклеотид для індукції батьківської експресії ube3a
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
MX2018005377A (es) 2015-11-30 2018-11-09 Univ Duke Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso.
JP6932698B2 (ja) 2015-12-01 2021-09-08 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ アルファ１アンチトリプシン欠乏症の治療のための材料および方法
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
AR108038A1 (es) 2016-03-14 2018-07-11 Roche Innovation Ct Copenhagen As Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1)
WO2017158422A1 (en) 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
WO2017180915A2 (en) 2016-04-13 2017-10-19 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP3449001B1 (de) 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Hemmung von mir-22-mirna durch apt-110
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
WO2018002762A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP4484443A3 (de) 2016-06-29 2025-03-26 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von friedreich-ataxie und anderen verwandten erkrankungen
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
JP7548696B2 (ja) 2016-07-06 2024-09-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
EP3487523B1 (de) 2016-07-19 2023-09-06 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
ES2837076T3 (es) 2016-09-01 2021-06-29 Proqr Therapeutics Ii Bv Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente
JP7206214B2 (ja) 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
KR20240096846A (ko) 2017-01-10 2024-06-26 애로우헤드 파마슈티컬스 인코포레이티드 알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법
EP3568480A1 (de) 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense-oligonukleotide zur modulierung der nfkb2-expression
US20190338286A1 (en) 2017-01-13 2019-11-07 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rel expression
US20190367920A1 (en) 2017-01-13 2019-12-05 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
EP3568481A1 (de) 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense-oligonukleotide zur modulierung der relb-expression
WO2018130581A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rela expression
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585807A1 (de) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2019030313A2 (en) 2017-08-11 2019-02-14 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019038228A1 (en) 2017-08-22 2019-02-28 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
JP2021502059A (ja) 2017-10-13 2021-01-28 ロシュ イノベーション センター コペンハーゲン エーエス 部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
AU2018350693B2 (en) 2017-10-16 2021-03-04 F. Hoffmann-La Roche Ag Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
US20190153440A1 (en) 2017-11-21 2019-05-23 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
BR112020009431A2 (pt) 2017-12-01 2020-10-13 The Texas A&M University System tratamento antisense da síndrome de angelman
CN111344408A (zh) 2017-12-11 2020-06-26 哥本哈根罗氏创新中心 用于调控fndc3b表达的寡核苷酸
WO2019115417A2 (en) 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
CA3084632A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a
CN111512160B (zh) 2017-12-21 2024-04-09 豪夫迈·罗氏有限公司 Htra1 rna拮抗剂的伴随诊断
US20200332289A1 (en) 2017-12-22 2020-10-22 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
CN111757936B (zh) 2017-12-22 2025-07-04 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间连接的寡核苷酸
US11597926B2 (en) 2017-12-22 2023-03-07 Roche Innovation Center Copenhagen A/S Thiophosphoramidites
WO2019137883A1 (en) 2018-01-10 2019-07-18 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating pias4 expression
JP2021511027A (ja) 2018-01-12 2021-05-06 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ アルファ−シヌクレインアンチセンスオリゴヌクレオチド及びその使用
CA3088112A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
JP2021510295A (ja) 2018-01-12 2021-04-22 ロシュ イノベーション センター コペンハーゲン エーエス Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド
KR102839166B1 (ko) 2018-01-12 2025-07-28 브리스톨-마이어스 스큅 컴퍼니 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도
EP3740574A1 (de) 2018-01-17 2020-11-25 Roche Innovation Center Copenhagen A/S Oligonukleotide zur modulierung der erc1-expression
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
IL320427A (en) 2018-02-21 2025-06-01 Bristol Myers Squibb Co CAMK2D antisense oligonucleotides and their uses
CA3092497A1 (en) 2018-03-19 2019-09-26 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and uses thereof
EP3775208A1 (de) 2018-04-05 2021-02-17 F. Hoffmann-La Roche AG Verwendung von fubp1-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
MY206038A (en) 2018-07-03 2024-11-26 Hoffmann La Roche Oligonucleotides for modulating tau expression
MX2021000404A (es) 2018-07-13 2021-03-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de rtel1.
CN112513060B (zh) 2018-07-31 2024-08-06 罗氏创新中心哥本哈根有限公司 包含三硫代磷酸酯核苷间键的寡核苷酸
US20210221837A1 (en) 2018-07-31 2021-07-22 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
CA3121191A1 (en) 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
CA3129646A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Novel phosphoramidites
CN113490742A (zh) 2019-02-20 2021-10-08 罗氏创新中心哥本哈根有限公司 膦酰基乙酸酯缺口聚物寡核苷酸
CA3132178A1 (en) 2019-04-02 2020-10-08 Aliye Seda Yilmaz-Elis Antisense oligonucleotides for immunotherapy
BR112021019182A2 (pt) 2019-04-03 2022-05-31 Bristol Myers Squibb Co Oligonucleotídeos angptl2 antissenso e seus usos
WO2020255007A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
US20220305107A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
CN114729392A (zh) 2019-09-06 2022-07-08 10X基因组学有限公司 用于对细胞和细胞珠粒进行条形码化的系统和方法
EP4077674A1 (de) 2019-12-18 2022-10-26 Alia Therapeutics S.R.L. Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
WO2022175815A1 (en) 2021-02-19 2022-08-25 Pfizer Inc. Methods of protecting rna
US20240141340A1 (en) 2021-03-05 2024-05-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for use in the treatment of corneal dystrophies
AU2022234522A1 (en) 2021-03-08 2023-10-26 Les Laboratoires Servier Antisense oligonucleotides for inhibiting alpha-synuclein expression
CN113274492B (zh) * 2021-05-21 2022-06-17 大连理工大学 一种基于羟基氧化铝纳米羧基改性的复合疫苗佐剂的制备方法
WO2023285431A1 (en) 2021-07-12 2023-01-19 Alia Therapeutics Srl Compositions and methods for allele specific treatment of retinitis pigmentosa
WO2023043220A1 (ko) 2021-09-16 2023-03-23 주식회사 큐마인 Wfdc2의 발현을 조절하는 안티센스 화합물
MX2024004177A (es) 2021-10-08 2024-04-23 Pfizer Composiciones inmunogenicas de lnp y metodos de los mismos.
EP4436595A1 (de) 2021-11-22 2024-10-02 Pfizer Inc. Verringerung des risikos von antigen-mimetika in immunogenen arzneimitteln
JP2024546993A (ja) 2021-12-17 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
EP4453196A1 (de) 2021-12-21 2024-10-30 Alia Therapeutics Srl Typ-ii-cas-proteine und anwendungen davon
JP2025504887A (ja) 2022-01-28 2025-02-19 ファイザー・インク コロナウイルス抗原バリアント
AU2023227443A1 (en) 2022-03-01 2024-10-10 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023194359A1 (en) 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024056880A2 (en) 2022-09-16 2024-03-21 Alia Therapeutics Srl Enqp type ii cas proteins and applications thereof
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2024105162A1 (en) 2022-11-16 2024-05-23 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2024134551A1 (en) 2022-12-23 2024-06-27 Pfizer Inc. Lipid particle compositions and methods of use thereof
CN120882867A (zh) 2023-01-11 2025-10-31 阿利亚治疗有限公司 Ii型cas蛋白及其应用
WO2025003344A1 (en) 2023-06-28 2025-01-02 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2025036916A1 (en) 2023-08-16 2025-02-20 Les Laboratoires Servier Oligonucleotides for modulating kcnt1 expression
WO2025210147A1 (en) 2024-04-04 2025-10-09 Alia Therapeutics Srl Type v cas proteins and applications thereof
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
AU651569B2 (en) * 1990-01-11 1994-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating RNA activity and gene expression
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
WO1991014696A1 (en) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
AU4848793A (en) * 1992-09-11 1994-04-12 Isis Pharmaceuticals, Inc. Oligonucleotide and nucleotide amine analogs, methods of synthesis and use

Also Published As

Publication number Publication date
CA2122030A1 (en) 1993-04-29
AU2916292A (en) 1993-05-21
EP1331011A2 (de) 2003-07-30
DE69233046D1 (de) 2003-06-12
EP0724447A4 (de) 1996-01-22
EP0724447B1 (de) 2003-05-07
EP1331011A3 (de) 2003-12-17
WO1993007883A1 (en) 1993-04-29
EP0724447A1 (de) 1996-08-07
JP2823959B2 (ja) 1998-11-11
DE69233046T2 (de) 2004-03-04
JPH06510791A (ja) 1994-12-01
CA2122030C (en) 1997-03-04

Similar Documents

Publication Publication Date Title
ATE239484T1 (de) Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
Proudnikov et al. Chemical methods of DNA and RNA fluorescent labeling
CA2333732A1 (en) Redox reversible imidazole-osmium complex conjugates
MX160856A (es) Mejoras en mecanismo diferencial para vehiculos
WO1991012023A3 (en) Hybrid reagents capable of selectively releasing molecules into cells
NO996107L (no) C-4"-substituerte makrolidderivater
DE69434299D1 (de) Nukleoside und oligonukleoside mit thiol-gruppe
DE69714600T2 (de) Verfahren zur markierung von nukleotiden, markierte nukleotide und nuetzliche zwischenprodukte
MX9203504A (es) Complejo agente: lipido activo de alta proporcion.
FI880405A7 (fi) Adenosin-5'-karboxamidderivat.
FI103181B1 (fi) Uusi vasta-aine ja siihen liittyvät vasta-ainekonjugaatit, DNA-sekvenssit, ilmentämisvehikkelit ja solut
ATE223461T1 (de) Helium-neon anregbare retikulozitfarbstoffe erhältlich aus halolepidinen
KR920012106A (ko) 표지된 변형 올리고뉴클레오티드
ATE141926T1 (de) Neue cobalamin-säurehydrazide und davon abgeleitete cobalamin-konjugate
KR920701220A (ko) 신규의 복핵 백금 착체 및 이를 유효성분으로하는 항종양제
IE45070L (en) Anthracycline glycoside antibiotics
DE3800644A1 (de) Verfahren zum hochspezifischen nachweis von nukleinsaeuren in loesung
DE4239531A1 (de) Reagenz zur Kupplung verschiedener Substanzen an Nukleinsäuren sowie Verfahren zu dessen Herstellung
Facompré et al. DNA targeting of two new antitumour rebeccamycin derivatives
BR8702662A (pt) Sistema de transmissao homocinetica para eixos desalinhados em ate 45 graus em qualquer direcao,garantindo o mesmo movimento em ambos os eixos
AU2739797A (en) (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides
IT1308393B1 (it) Supporto per barra (e) con alloggiamento (i) in grado di riceverebarre di sezioni trasversali differenti.
WO1998004575A3 (en) Lipophilic oligonucleotide analogs
IT8621205A0 (it) Supporto pieghevole per impedire lo spostamento di corpi rotolanti, in particolare ruote di veicoli.
Bikbulatov et al. Investigation of teratogenic, embryotoxic, mutagenic, and immunosuppressive effect of 5-bromouridine.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties